SCHEMBL4515494

SCHEMBL4515494

CC1(O)CCC(N2CCC(Cc3ccc(OCC(=O)Nc4ccc(F)cc4)cc3Cl)C2=O)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.43
APOBEC3A P31941 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 3/20 0.41
MAPT P10636 1/20 0.41
AHR P35869 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KMT2A Q03164 3/20 0.40
GAA P10253 2/20 0.39
MCHR1 Q99705 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
BACE1 P56817 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4514699 0.92 MDH1 (0.41) ALDH1A1MAPTSMN1; SMN2KMT2AGAA
SCHEMBL4511135 0.87 ATF4 (0.47) HPGDALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL4509399 0.86 MCL1 (0.39) HPGDALDH1A1GAA
SCHEMBL13674510 0.86 ALDH1A1 (0.38) L3MBTL1ALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL4504293 0.85 ALDH1A1 (0.41) L3MBTL1ALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL4512718 0.85 ALDH1A1 (0.36) ALDH1A1GAA
SCHEMBL5543837 0.84 P2RX7 (0.43)
SCHEMBL4509276 0.83 ALDH1A1 (0.40) HPGDL3MBTL1ALDH1A1KMT2AGAA
SCHEMBL4508294 0.83 ALDH1A1 (0.43) HPGDL3MBTL1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL4510855 0.82 ALDH1A1 (0.39) HPGDL3MBTL1ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HPGD 63/4885APOBEC3A 4256/4885APOBEC3G 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.